NEW YORK, Oct. 11, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Several cell culture-derived biopharmaceutical drugs were launched in the US and European markets in 2010. Biopharmaceuticals (recombinant proteins, monoclonal antibody and nucleic acid-based products) represent the fastest growing sector in the pharmaceutical industry. Driving the extraordinary interest in biopharmaceuticals is the ability of these large proteins to target diseases in a very specific manner, thus maximizing efficacy while minimizing side effects.
Growth in the development and production of biopharmaceuticals is the most significant driver of the cell culture market. Biological products are developed from large and complex protein molecules, which require equally complex manufacturing methods and an array of analytical techniques. Protein-based biopharmaceuticals are invariably produced by an initial cell culture step (upstream processing), followed by product recovery, purification and formulation into final product format (downstream processing).
This report analyzes the world market for the cell cultures used in these steps and the major trends driving this market. Forecasts and current market sizing are provided in three specific segments:
Copyright©2010 PR Newswire.
All rights reserved